膵外分泌機能不全の世界市場レポート 2024年

膵外分泌機能不全の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.5%の年間複合成長率（CAGR）で33億4,000万米ドルに成長すると予想されます。予測期間で予想される成長は、膵外分泌機能不全（EPI）の意識とスクリーニングの継続的な増加、高齢者人口の拡大、慢性疾患の発生率の増加、医療サービスなど、いくつかの要因によるものと考えられます。消化器の健康分野における研究開発。予測期間中に予想される主要動向には、遠隔医療とデジタル医療ソリューションの導入、共同調査の取り組み、小児EPIへの注力、規制の進歩とファストトラック指定、新興国での市場拡大、医療インフラの進歩などが含まれます。これらの動向は集合的に、膵外分泌機能不全の管理と理解において予測される成長と発展に貢献します。

予測される慢性疾患の急増は、今後数年間で膵外分泌機能不全市場の拡大を促進する原動力となる見込みです。慢性疾患には、多くの場合3か月を超える長期間にわたって持続する持続的な病状が含まれます。これらの疾患の長期にわたる発生は、膵外分泌機能不全などの二次的な合併症のリスクを高め、医療介入や治療による管理強化の必要性を促します。結果として、これらの介入は、そのような症状に対処している個人の寿命を潜在的に延長することに貢献します。たとえば、2023年1月に国立医学図書館が発行した報告書は、米国で1つ以上の慢性疾患に罹患している50歳以上の人口が99.5%増加し、2050年までに1億4,266万人に達すると予想されることを強調しました。したがって、慢性疾患の急増が膵外分泌機能不全市場の成長を促進すると予想されます。

糖尿病の症例の増加は、膵外分泌機能不全市場の成長を促進すると予想されます。糖尿病は、体内でのインスリンの生成または利用が不十分であることを特徴とする慢性的な健康状態であり、血流中に過剰な血糖の蓄積を引き起こします。 膵外分泌機能不全（EPI）に適切な消化酵素を供給し、体内のインスリンレベルを維持するには、膵臓酵素補充療法（PERT）が不可欠になります。たとえば、2023年 6月のInstitute for Health Metrics and Evaluationの報告書では、世界の糖尿病患者数は2022年の5億2,900万人から2050年までに13億人に達すると予測されています。したがって、糖尿病の有病率の増加が膵外分泌機能不全の成長を促進すると予想されます。市場。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の膵外分泌機能不全市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の膵外分泌機能不全の市場規模実績と成長率、2018～2023年
• 世界の膵外分泌機能不全市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の膵外分泌機能不全市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 栄養管理
• 膵臓酵素補充療法（PERT）
• その他
• 世界の膵外分泌機能不全市場、診断別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 画像検査
• コンピュータ断層撮影（CT）スキャン
• 腹部超音波検査
• セクレチン膵機能検査
• 便脂肪検査
• 糞便エラスターゼ検査（FE-1）
• その他
• 世界の膵外分泌機能不全市場、症状別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 腹痛
• 便秘
• 下痢
• 脂肪便
• 減量
• その他
• 世界の膵外分泌機能不全市場、流通チャネル別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の膵外分泌機能不全市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• 専門クリニック
• 在宅医療

第7章 地域と国の分析

• 世界の膵外分泌機能不全市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の膵外分泌機能不全市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膵外分泌機能不全市場の競合情勢
• 膵外分泌機能不全市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Merck &Co. Inc.
  • Janssen Pharmaceuticals Inc.
  • AbbVie Inc.

第31章 その他の大手と革新的な企業

• Bayer AG
• Novartis AG
• Sanofi SA
• AstraZeneca plc
• Medtronic plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Nestle Health Science SA
• Allergan plc
• Chiesi Farmaceutici SpA
• Wockhardt Ltd.
• Amryt Pharma Plc
• Codexis Inc.
• Nordmark Arzneimittel GmbH &Co. KG
• Aimmune Therapeutics Inc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the insufficient production or release of digestive enzymes by the pancreas into the small intestine. These enzymes are crucial for the proper digestion and absorption of nutrients from ingested food. Exocrine pancreatic insufficiency can result in malnutrition and various digestive symptoms, such as diarrhea, abdominal pain, bloating, and weight loss.

The primary types of treatments for exocrine pancreatic insufficiency include nutritional management, pancreatic enzyme replacement therapy (PERT), and other interventions. Nutritional management involves planning and implementing dietary strategies to optimize an individual's nutritional status, supporting overall health and well-being. This approach is essential in the comprehensive care of individuals with exocrine pancreatic insufficiency (EPI), diagnosed through imaging tests such as Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), and others. These diagnostic tests help identify symptoms such as abdominal pain, constipation, diarrhea, fatty stool, and weight loss. The drugs used for treating exocrine pancreatic insufficiency are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets. These medications are utilized by end users such as hospitals, specialty clinics, and individuals receiving care at home.

The exocrine pancreatic insufficiency market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency market statistics, including exocrine pancreatic insufficiency industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency market share, detailed exocrine pancreatic insufficiency market segments, market trends and opportunities, and any further data you may need to thrive in the exocrine pancreatic insufficiency industry. This exocrine pancreatic insufficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.41 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth observed in the historical period can be attributed to several factors, including increased awareness and diagnosis of exocrine pancreatic insufficiency (EPI), a growing prevalence of digestive disorders, an aging population, and the associated decline in pancreatic function, as well as a rise in gastrointestinal surgeries. These factors collectively contribute to the increased recognition and incidence of exocrine pancreatic insufficiency during the historic period.

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The anticipated growth in the forecast period can be attributed to several factors, including a continued increase in awareness and screening for exocrine pancreatic insufficiency (EPI), an expanding geriatric population, a rising incidence of chronic diseases, improvements in patient access to healthcare services, and ongoing research and development in the field of digestive health. Major trends expected in the forecast period encompass the adoption of telehealth and digital health solutions, collaborative research initiatives, a focus on pediatric EPI, regulatory advances and fast-track designations, market expansion in emerging economies, and advancements in healthcare infrastructure. These trends collectively contribute to the projected growth and development in the management and understanding of exocrine pancreatic insufficiency.

The anticipated surge in chronic diseases is poised to be a driving force behind the expansion of the exocrine pancreatic insufficiency market in the coming years. Chronic diseases encompass enduring medical conditions that persist over an extended period, often exceeding three months. Prolonged occurrences of these diseases elevate the risk of secondary complications such as exocrine pancreatic insufficiency, prompting the need for enhanced management through medical interventions and therapies. Consequently, these interventions contribute to potentially prolonged lifespans for individuals dealing with such conditions. For example, a report published by the National Library of Medicine in January 2023 highlighted a projected 99.5% increase in individuals aged 50 years and above, affected by one or more chronic illnesses, expected to reach 142.66 million by 2050 in the United States, up from 71.522 million in 2020. Therefore, the surge in chronic diseases is anticipated to drive the exocrine pancreatic insufficiency market's growth.

The escalating cases of diabetes are expected to fuel the growth of the exocrine pancreatic insufficiency market. Diabetes, a chronic health condition characterized by inadequate insulin production or utilization by the body, leads to an accumulation of excessive blood sugar in the bloodstream. Pancreatic enzyme replacement treatment (PERT) becomes essential to supply adequate digestive enzymes for exocrine pancreatic insufficiency (EPI) and maintain the body's insulin levels. For instance, a report from the Institute for Health Metrics and Evaluation in June 2023 projected global diabetes cases to reach 1.3 billion by 2050, up from 529 million in 2022. Therefore, the increasing prevalence of diabetes is expected to drive the growth of the exocrine pancreatic insufficiency market.

Escalating medical expenses stand as a primary restraint for the exocrine pancreatic insufficiency (EPI) market in the foreseeable future. The rising costs within the EPI market can limit patient access to crucial medications and treatments, potentially leading to delayed or suboptimal care, thus negatively impacting patient outcomes. Additionally, healthcare providers and payers grappling with budget constraints due to escalating medical expenses might encounter challenges in maintaining availability and reimbursement of EPI treatments. This difficulty may hinder the approval and widespread adoption of innovative therapies. For instance, a report from the American Hospital Association in April 2023 indicated that 84% of hospitals experienced increased costs due to adherence to insurer policies. Drug expenses per patient saw a 36.9% growth, while non-labor expenses increased from 8.2% in January 2019 to approximately 10.6% in January 2022. Therefore, rising medical costs are anticipated to impede the growth of the exocrine pancreatic insufficiency market in the forecast period.

Leading companies within the exocrine pancreatic insufficiency (EPI) market are prioritizing the establishment of patient advocacy groups to drive patient-centric product development. These advocacy groups in the realm of EPI are dedicated organizations focused on supporting and advocating for individuals affected by exocrine pancreatic insufficiency, empowering them to access information about their condition and available treatment options. For instance, in November 2021, Aimmune Therapeutics, Inc., a US-based biopharmaceutical firm specializing in EPI and chronic pancreatitis treatment, collaborated with Mission Cure, a nonprofit organization in the US dedicated to EPI treatment. Together, they launched an online patient community on the HealthUnlocked network, providing vital support and information to pancreatitis patients, including those dealing with exocrine pancreatic insufficiency (EPI). This platform serves as a space for patients to connect, share experiences, and receive support in managing chronic pancreatitis and related conditions.

In September 2021, AzurRx BioPharma Inc., a US-based pharmaceutical company, completed the acquisition of First Wave Bio Inc. for $229 million. This strategic acquisition enabled AzurRx to broaden its range of therapies for gastrointestinal illnesses and leverage the expertise of First Wave Bio in drug research and formulation. Additionally, this acquisition bolstered AzurRx's position in the market by offering a more extensive array of solutions addressing unmet medical needs, particularly in gastrointestinal conditions such as exocrine pancreatic insufficiency (EPI). First Wave Bio Inc., also based in the United States, specializes in developing medications for gastrointestinal disorders, including EPI.

Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan plc, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma Plc, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc, Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics

North America was the largest region in the exocrine pancreatic insufficiency market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the exocrine pancreatic insufficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The exocrine pancreatic insufficiency market consists of revenues earned by entities by providing enzyme replacement therapy, nutritional counseling, monitoring, managing underlying conditions, lifestyle modifications, and gastroenterology consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency market also includes sales of Creon, zenpep, pancreaze, ultresa, and viokace. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Exocrine Pancreatic Insufficiency Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The exocrine pancreatic insufficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Other Treatments
• 2) By Diagnosis: Imaging Tests; Computed Tomography (CT) Scan; Abdominal Ultrasound; Secretin Pancreatic Function Test; Fecal Fat Test; Fecal Elastase Test (FE-1); Other Types
• 3) By Symptoms: Abdominal Pain; Constipation; Diarrhea; Fatty Stools; Weight Loss; Other Symptoms
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End Users: Hospitals; Specialty Clinics; Homecare
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency Market Characteristics

3. Exocrine Pancreatic Insufficiency Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Exocrine Pancreatic Insufficiency Market Size and Growth

• 5.1. Global Exocrine Pancreatic Insufficiency Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Exocrine Pancreatic Insufficiency Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Exocrine Pancreatic Insufficiency Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Exocrine Pancreatic Insufficiency Market Segmentation

• 6.1. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Nutritional Management
• Pancreatic Enzyme Replacement Therapy (PERT)
• Other Treatments
• 6.2. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Imaging Tests
• Computed Tomography (CT) Scan
• Abdominal Ultrasound
• Secretin Pancreatic Function Test
• Fecal Fat Test
• Fecal Elastase Test (FE-1)
• Other Types
• 6.3. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Symptoms, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Abdominal Pain
• Constipation
• Diarrhea
• Fatty Stools
• Weight Loss
• Other Symptoms
• 6.4. Global Exocrine Pancreatic Insufficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare

7. Exocrine Pancreatic Insufficiency Market Regional And Country Analysis

• 7.1. Global Exocrine Pancreatic Insufficiency Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Exocrine Pancreatic Insufficiency Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency Market

• 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Exocrine Pancreatic Insufficiency Market

• 9.1. China Exocrine Pancreatic Insufficiency Market Overview
• 9.2. China Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Exocrine Pancreatic Insufficiency Market

• 10.1. India Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency Market

• 11.1. Japan Exocrine Pancreatic Insufficiency Market Overview
• 11.2. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency Market

• 12.1. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency Market

• 13.1. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency Market

• 14.1. South Korea Exocrine Pancreatic Insufficiency Market Overview
• 14.2. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency Market

• 15.1. Western Europe Exocrine Pancreatic Insufficiency Market Overview
• 15.2. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Exocrine Pancreatic Insufficiency Market

• 16.1. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency Market

• 17.1. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Exocrine Pancreatic Insufficiency Market

• 18.5. France Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency Market

• 19.9. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency Market

• 20.13. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency Market

• 21.1. Eastern Europe Exocrine Pancreatic Insufficiency Market Overview
• 21.2. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency Market

• 22.1. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Exocrine Pancreatic Insufficiency Market

• 23.1. North America Exocrine Pancreatic Insufficiency Market Overview
• 23.2. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Exocrine Pancreatic Insufficiency Market

• 24.1. USA Exocrine Pancreatic Insufficiency Market Overview
• 24.2. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency Market

• 25.1. Canada Exocrine Pancreatic Insufficiency Market Overview
• 25.2. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Exocrine Pancreatic Insufficiency Market

• 26.1. South America Exocrine Pancreatic Insufficiency Market Overview
• 26.2. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency Market

• 27.1. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency Market

• 28.1. Middle East Exocrine Pancreatic Insufficiency Market Overview
• 28.2. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency Market

• 29.1. Africa Exocrine Pancreatic Insufficiency Market Overview
• 29.2. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Exocrine Pancreatic Insufficiency Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Exocrine Pancreatic Insufficiency Market Competitive Landscape And Company Profiles

• 30.1. Exocrine Pancreatic Insufficiency Market Competitive Landscape
• 30.2. Exocrine Pancreatic Insufficiency Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Janssen Pharmaceuticals Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AbbVie Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Exocrine Pancreatic Insufficiency Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi S.A.
• 31.4. AstraZeneca plc
• 31.5. Medtronic plc
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Nestle Health Science S.A.
• 31.9. Allergan plc
• 31.10. Chiesi Farmaceutici S.p.A.
• 31.11. Wockhardt Ltd.
• 31.12. Amryt Pharma Plc
• 31.13. Codexis Inc.
• 31.14. Nordmark Arzneimittel GmbH & Co. KG
• 31.15. Aimmune Therapeutics Inc

32. Global Exocrine Pancreatic Insufficiency Market Competitive Benchmarking

33. Global Exocrine Pancreatic Insufficiency Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency Market

35. Exocrine Pancreatic Insufficiency Market Future Outlook and Potential Analysis

• 35.1 Exocrine Pancreatic Insufficiency Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Exocrine Pancreatic Insufficiency Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Exocrine Pancreatic Insufficiency Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer